Moderna (NASDAQ: MRNA) shareholders have been having a rough time lately. The biotech stock rocketed higher last spring, but ...

Is Moderna a no-brainer buy on the sell-off? I wouldn't go that far. Investors should think long and hard about the company's ...

Stéphane Bancel, CEO of mRNA specialist Moderna, delivered some difficult truths to shareholders about the company’s ...

Moderna now expects 2025 revenue to come in between $1.5 billion and $2.5 billion, most of which will come in the second half ...

It was an extremely busy week in the biotech sector, with several companies making important presentations at the J.P. Morgan ...

The biotech company said it anticipates between $1.5 billion and $2.5 billion in revenue this year, below Wall Street ...

Moderna's shares plummeted after cutting its revenue guidance for 2025 due to slow demand for Covid and RSV vaccines.

The current public-health risk is low, but the CDC is working with states to monitor people with animal exposure.

Moderna provides updates on its business and pipeline progress at the J.P. Morgan Healthcare Conference. Moderna reported preliminary product sales between $3 billion and $3.1 billion for 2024 ...